ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Biliary Cholangitis Therapeutics Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-11W14373
Home | Market Reports | Health| Health Conditions| Cancer
Global Primary Biliary Cholangitis Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Primary Biliary Cholangitis Therapeutics Market Insights, Forecast to 2030

Code: QYRE-Auto-11W14373
Report
December 2024
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Abbott Laboratories
Allergan plc
Eli Lilly and Co
Intercept Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd

Primary Biliary Cholangitis Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Primary Biliary Cholangitis Therapeutics Market

Primary Biliary Cholangitis Therapeutics Market

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.
Market Analysis and Insights: Global Primary Biliary Cholangitis Therapeutics Market
The global Primary Biliary Cholangitis Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Primary Biliary Cholangitis Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Primary Biliary Cholangitis Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Primary Biliary Cholangitis Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Primary Biliary Cholangitis Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Primary Biliary Cholangitis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Primary Biliary Cholangitis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Primary Biliary Cholangitis Therapeutics Market Report

Report Metric Details
Report Name Primary Biliary Cholangitis Therapeutics Market
CAGR 5%
Segment by Type
  • OCALIVA
  • Ursodiol
  • Others
Segment by Application
  • Hospital
  • Private Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Primary Biliary Cholangitis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Primary Biliary Cholangitis Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Biliary Cholangitis Therapeutics revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Primary Biliary Cholangitis Therapeutics Market report?

Ans: The main players in the Primary Biliary Cholangitis Therapeutics Market are Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd.

What are the Application segmentation covered in the Primary Biliary Cholangitis Therapeutics Market report?

Ans: The Applications covered in the Primary Biliary Cholangitis Therapeutics Market report are Hospital, Private Clinic, Other

What are the Type segmentation covered in the Primary Biliary Cholangitis Therapeutics Market report?

Ans: The Types covered in the Primary Biliary Cholangitis Therapeutics Market report are OCALIVA, Ursodiol, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 OCALIVA
1.2.3 Ursodiol
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Private Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Biliary Cholangitis Therapeutics Market Perspective (2019-2030)
2.2 Global Primary Biliary Cholangitis Therapeutics Growth Trends by Region
2.2.1 Primary Biliary Cholangitis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Primary Biliary Cholangitis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Primary Biliary Cholangitis Therapeutics Market Dynamics
2.3.1 Primary Biliary Cholangitis Therapeutics Industry Trends
2.3.2 Primary Biliary Cholangitis Therapeutics Market Drivers
2.3.3 Primary Biliary Cholangitis Therapeutics Market Challenges
2.3.4 Primary Biliary Cholangitis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Primary Biliary Cholangitis Therapeutics by Players
3.1.1 Global Primary Biliary Cholangitis Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Primary Biliary Cholangitis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Primary Biliary Cholangitis Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Primary Biliary Cholangitis Therapeutics Market Concentration Ratio
3.4.1 Global Primary Biliary Cholangitis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Biliary Cholangitis Therapeutics Revenue in 2023
3.5 Global Key Players of Primary Biliary Cholangitis Therapeutics Head office and Area Served
3.6 Global Key Players of Primary Biliary Cholangitis Therapeutics, Product and Application
3.7 Global Key Players of Primary Biliary Cholangitis Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Biliary Cholangitis Therapeutics Breakdown Data by Type
4.1 Global Primary Biliary Cholangitis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Primary Biliary Cholangitis Therapeutics Breakdown Data by Application
5.1 Global Primary Biliary Cholangitis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Primary Biliary Cholangitis Therapeutics Market Size (2019-2030)
6.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Type
6.2.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024)
6.2.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030)
6.2.3 North America Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
6.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Application
6.3.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024)
6.3.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030)
6.3.3 North America Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
6.4 North America Primary Biliary Cholangitis Therapeutics Market Size by Country
6.4.1 North America Primary Biliary Cholangitis Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024)
6.4.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Primary Biliary Cholangitis Therapeutics Market Size (2019-2030)
7.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type
7.2.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024)
7.2.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030)
7.2.3 Europe Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
7.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application
7.3.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024)
7.3.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030)
7.3.3 Europe Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
7.4 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country
7.4.1 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024)
7.4.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Primary Biliary Cholangitis Therapeutics Market Size (2019-2030)
8.2 China Primary Biliary Cholangitis Therapeutics Market Size by Type
8.2.1 China Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024)
8.2.2 China Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030)
8.2.3 China Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
8.3 China Primary Biliary Cholangitis Therapeutics Market Size by Application
8.3.1 China Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024)
8.3.2 China Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030)
8.3.3 China Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Primary Biliary Cholangitis Therapeutics Market Size (2019-2030)
9.2 Asia Primary Biliary Cholangitis Therapeutics Market Size by Type
9.2.1 Asia Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024)
9.2.2 Asia Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030)
9.2.3 Asia Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
9.3 Asia Primary Biliary Cholangitis Therapeutics Market Size by Application
9.3.1 Asia Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024)
9.3.2 Asia Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030)
9.3.3 Asia Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
9.4 Asia Primary Biliary Cholangitis Therapeutics Market Size by Region
9.4.1 Asia Primary Biliary Cholangitis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Primary Biliary Cholangitis Therapeutics Market Size by Region (2019-2024)
9.4.3 Asia Primary Biliary Cholangitis Therapeutics Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Developments
11.2 Allergan Plc
11.2.1 Allergan Plc Company Details
11.2.2 Allergan Plc Business Overview
11.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Introduction
11.2.4 Allergan Plc Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
11.2.5 Allergan Plc Recent Developments
11.3 Eli Lilly and Co.
11.3.1 Eli Lilly and Co. Company Details
11.3.2 Eli Lilly and Co. Business Overview
11.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Introduction
11.3.4 Eli Lilly and Co. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
11.3.5 Eli Lilly and Co. Recent Developments
11.4 Intercept Pharmaceuticals Inc.
11.4.1 Intercept Pharmaceuticals Inc. Company Details
11.4.2 Intercept Pharmaceuticals Inc. Business Overview
11.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Introduction
11.4.4 Intercept Pharmaceuticals Inc. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
11.4.5 Intercept Pharmaceuticals Inc. Recent Developments
11.5 Takeda Pharmaceutical Co. Ltd.
11.5.1 Takeda Pharmaceutical Co. Ltd. Company Details
11.5.2 Takeda Pharmaceutical Co. Ltd. Business Overview
11.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Introduction
11.5.4 Takeda Pharmaceutical Co. Ltd. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
11.5.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Abbott Laboratories
Allergan plc
Eli Lilly and Co
Intercept Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
List of Tables
    Table 1. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of OCALIVA
    Table 3. Key Players of Ursodiol
    Table 4. Key Players of Others
    Table 5. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Primary Biliary Cholangitis Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Primary Biliary Cholangitis Therapeutics Market Share by Region (2019-2024)
    Table 9. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Primary Biliary Cholangitis Therapeutics Market Share by Region (2025-2030)
    Table 11. Primary Biliary Cholangitis Therapeutics Market Trends
    Table 12. Primary Biliary Cholangitis Therapeutics Market Drivers
    Table 13. Primary Biliary Cholangitis Therapeutics Market Challenges
    Table 14. Primary Biliary Cholangitis Therapeutics Market Restraints
    Table 15. Global Primary Biliary Cholangitis Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Players (2019-2024)
    Table 17. Global Top Primary Biliary Cholangitis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Therapeutics as of 2023)
    Table 18. Global Primary Biliary Cholangitis Therapeutics Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Primary Biliary Cholangitis Therapeutics, Headquarters and Area Served
    Table 21. Global Key Players of Primary Biliary Cholangitis Therapeutics, Product and Application
    Table 22. Global Key Players of Primary Biliary Cholangitis Therapeutics, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2019-2024)
    Table 26. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Type (2025-2030)
    Table 28. Global Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Application (2019-2024)
    Table 30. Global Primary Biliary Cholangitis Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Application (2025-2030)
    Table 32. North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Primary Biliary Cholangitis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Primary Biliary Cholangitis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Primary Biliary Cholangitis Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Primary Biliary Cholangitis Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Primary Biliary Cholangitis Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Abbott Laboratories Company Details
    Table 65. Abbott Laboratories Business Overview
    Table 66. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product
    Table 67. Abbott Laboratories Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024) & (US$ Million)
    Table 68. Abbott Laboratories Recent Developments
    Table 69. Allergan Plc Company Details
    Table 70. Allergan Plc Business Overview
    Table 71. Allergan Plc Primary Biliary Cholangitis Therapeutics Product
    Table 72. Allergan Plc Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024) & (US$ Million)
    Table 73. Allergan Plc Recent Developments
    Table 74. Eli Lilly and Co. Company Details
    Table 75. Eli Lilly and Co. Business Overview
    Table 76. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product
    Table 77. Eli Lilly and Co. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024) & (US$ Million)
    Table 78. Eli Lilly and Co. Recent Developments
    Table 79. Intercept Pharmaceuticals Inc. Company Details
    Table 80. Intercept Pharmaceuticals Inc. Business Overview
    Table 81. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product
    Table 82. Intercept Pharmaceuticals Inc. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024) & (US$ Million)
    Table 83. Intercept Pharmaceuticals Inc. Recent Developments
    Table 84. Takeda Pharmaceutical Co. Ltd. Company Details
    Table 85. Takeda Pharmaceutical Co. Ltd. Business Overview
    Table 86. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product
    Table 87. Takeda Pharmaceutical Co. Ltd. Revenue in Primary Biliary Cholangitis Therapeutics Business (2019-2024) & (US$ Million)
    Table 88. Takeda Pharmaceutical Co. Ltd. Recent Developments
    Table 89. Research Programs/Design for This Report
    Table 90. Key Data Information from Secondary Sources
    Table 91. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Primary Biliary Cholangitis Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. OCALIVA Features
    Figure 4. Ursodiol Features
    Figure 5. Others Features
    Figure 6. Global Primary Biliary Cholangitis Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Primary Biliary Cholangitis Therapeutics Market Share by Application: 2023 VS 2030
    Figure 8. Hospital Case Studies
    Figure 9. Private Clinic Case Studies
    Figure 10. Other Case Studies
    Figure 11. Primary Biliary Cholangitis Therapeutics Report Years Considered
    Figure 12. Global Primary Biliary Cholangitis Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Primary Biliary Cholangitis Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Primary Biliary Cholangitis Therapeutics Market Share by Region: 2023 VS 2030
    Figure 15. Global Primary Biliary Cholangitis Therapeutics Market Share by Players in 2023
    Figure 16. Global Top Primary Biliary Cholangitis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Therapeutics as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue in 2023
    Figure 18. North America Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
    Figure 20. North America Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
    Figure 21. North America Primary Biliary Cholangitis Therapeutics Market Share by Country (2019-2030)
    Figure 22. United States Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Primary Biliary Cholangitis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
    Figure 26. Europe Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
    Figure 27. Europe Primary Biliary Cholangitis Therapeutics Market Share by Country (2019-2030)
    Figure 28. Germany Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Primary Biliary Cholangitis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
    Figure 36. China Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
    Figure 37. Asia Primary Biliary Cholangitis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
    Figure 39. Asia Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
    Figure 40. Asia Primary Biliary Cholangitis Therapeutics Market Share by Region (2019-2030)
    Figure 41. Japan Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Primary Biliary Cholangitis Therapeutics Market Share by Country (2019-2030)
    Figure 51. Brazil Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Primary Biliary Cholangitis Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Abbott Laboratories Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
    Figure 58. Allergan Plc Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
    Figure 59. Eli Lilly and Co. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
    Figure 60. Intercept Pharmaceuticals Inc. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
    Figure 61. Takeda Pharmaceutical Co. Ltd. Revenue Growth Rate in Primary Biliary Cholangitis Therapeutics Business (2019-2024)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Primary Biliary Cholangitis Therapeutics Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-11W14373
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Hurthle Cell Carcinoma Treatment Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-35B1140
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Anaplastic Large Cell Lymphoma Drugs Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-27H888
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Anaplastic Large Cell Lymphoma Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-16R5994
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions